Can PAR score PAR in the next biotech readout?

Good morning, Armchair Army,

Welcome to today's edition of The Armchair Analyst, a 5-minute daily update on the ASX life-sciences sector.

There is movement at the station.

This is the three-month chart for ASX-listed Paradigm (ASX: PAR).

In the last two days… green candlesticks on large volumes

Why?

Punters have entered the building.

The company is scheduled to announce Phase 3 interim results in a few weeks.

… and people want to speculate on the outcome of those results.

The condition?

Osteoarthritis (knee pain).

I’ve written before about share price action ahead of a clinical trial readout.

But here is a quick reminder…

As the result approaches, interest builds, speculation creeps in, and new investors enter the stock hoping to be positioned ahead of a positive outcome. 

ALSO, existing holders are less inclined to sell because they want exposure to the result. 

With fewer sellers and more buyers, prices rise, sometimes quickly.

The trick with these types of catalyst bets is to identify the companies BEFORE the run-up to a result.

This is generally how it plays out in a risk-on market.

But in a risk-off market, that “run-up” before results can be muted (and sometimes there is selling as people look to de-risk before the results).

I went back and looked at the price action around major binary clinical trial readouts on the ASX in 2026.

Four had sustained run-ups into the results (ACW, IMM, AVE and CYP), but for these companies investors tended to be risk-off immediately before the trial:

The only stock that really fit the “up and to the right” pattern was AVE.

For me, Paradigm's stock price movement before the trial results is the ‘tell’.

Are we risk-on?

Are we risk-off?

Some things to note about the Paradigm cap structure.

FIRST, the convertible note.

Paradigm still has a large convertible debt facility, and last night after the market closed, the holder converted another 7.6 million shares (at 15 cents).

So while the buyers may be coming in thick and fast, there may still be selling pressure from the note.

SECOND, the listed options.

There are also some short-dated listed options to watch.

About 120 million options that are exercisable at ~24 cents are set to expire in December.

These come with a piggyback too.

So, with a good result (and a share price rise above 24 cents), some of those options may convert, putting pressure on the share price around that level.

But the real mover of the price (up or down) is the result.

Good result?

Biotech is back, and we move closer to “risk-on”

Bad result?

A lot of capital BBQed, and we move closer to “risk-off”.

ALSO, after these interim results, we won’t have to wait long for the full readout, scheduled for early next year.

Between the convertible debt holder, the speculating traders entering and the listed options…

The buying and selling dynamics for Paradigm are very interesting.

Who knows how it will trade.

But it all comes down to the result.

No “base” case scenario here. Just Bull and Bear and Mega Bull.

Results in the next 4 weeks.

My full take on the trial:

Watch this space.

Let’s dive in…

Entropy Neurodynamics (ASX: ENP) signs pre-CTA with University of California for a US Phase 2 trial evaluating psychedelic IV treatment in a head-to-head trial against a leading SSRI in Major Depressive Disorder. (ENP)

🪑 Very, very good update.

This is an “up to 80-patient” Phase 2 clinical trial in a head-to-head study against the most widely used antidepressant in the world.

So far, ENP has done only small patient studies, but this is a large-scale study that should put the company on the radar of bigger players in the space.

(provided the data is good)

In the last 12 months, there have been three major transactions in the psychedelics space, with Eli Lilly taking out Ataibeckley for US$3.8 billion.

Leading the trial is Professor Carhart-Harris, a very influential neuroscientist in the psychedelics space.

ENP is evolving into a clinical-stage company - and, off the back of this trial, will have meaningful data to show that its IV-psilocybin product (hopefully) works.

The next stage will be setting up an IND in the US, with Phase 2 scheduled to start first quarter next year.

Noxopharm Limited (ASX: NOX) preclinical data showing its Sofra™ mRNA technology enhances immune responses to dying cancer cells. (NOX)

🪑 Nice update.

In my opinion, the best company on the ASX leveraged to the “Cancer Vaccine” theme (one that Moderna put on the map last week).

Radiopharm Theranostics (ASX: RAD) doses the first patient in the second cohort of its Phase 1/2a trial for RV-01 in B7-H3 tumours. (RAD)

🪑 Milestone ticked.

Genetic Signatures (ASX: GSS) is in merger discussions with Microba (ASX: MAP). (GSS)

BCAL Diagnostics (ASX: BDX) increased its stake in Genetic Signatures to 18.46% through an off-market purchase of 18.75 million shares for $1.5 million. (BDX)

🪑 Get your popcorn out for this one 🍿

I’ve dialled into the GSS investor call scheduled this morning. 

My full take on the situation tomorrow morning.

Roche and Eli Lilly secure 510(k) approval for the first rule-in, rule-out Alzheimer's blood test. (Fierce Biotech)

🪑 This is genuinely awesome news.

Neurotech International’s (ASX: NTI) Phase 3 program for autism spectrum disorder was featured on the 7:00 news last night (held):

PolyNovo (ASX: PNV) reports FY26 total revenue of $150.0M, a 16.1% increase, and a positive EBITDA of $12.1M. (PNV)

🪑 The market did not love the results… Down 10% on open.

Biome Australia (ASX: BIO) reports record growth with FY26 net profit after tax of $3.6M on $23.9M revenue (up 30% yoy). (BIO)

🪑 The market did like the results… Up 10% on open.

Enlitic (ASX: ENL) reminds eligible CDI holders of the Security Purchase Plan deadline this Friday. (ENL)

Prescient Therapeutics (ASX: PTX) opens a $7 million Share Purchase Plan at $0.065 per share. (PTX)

McKesson to acquire Precision Medicine Group for $2.25B, expanding oncology drug development and CRO services. (Reuters)

🪑 Interesting peer comp for the value of large CRO services businesses. 

RadPartners signs A$1B deal to acquire Everlight Radiology. (AFR)

🪑 Sydney-based Everlight Radiology provides 24/7 teleradiology services. 

It uses a global network of over 800 consultant radiologists to read and report on CT, MRI, and X-ray scans for hospitals and healthcare groups.

Book this as good private equity investing.

See you tomorrow,

The Armchair Analyst.